MPN Congress 2022 | Topics in CML: drug therapy revisited, third-line treatment, TFR update

Name: Topics in CML: drug therapy revisited, third-line treatment, TFR update
Uploaded: 2022-11-24T00:00:00Z
Description: Rüdiger Hehlmann, MD, PhD, Heidelberg University, Heidelberg, Germany, gives a presentation on advances in treatments for chronic myeloid leukemia (CML), managing CML in the third-line setting, and tyrosine kinase discontinuation (TKI) at the 14th International Congress on Myeloproliferative Neoplasms (MPNs) held in New York City, NY.

Rüdiger Hehlmann • 24 Nov 2022

MPN Congress 2022

Chronic Myeloid Leukemia Leukemia Asciminib Bosutinib Dasatinib Nilotinib Olverembatinib Ponatinib

ASCEMBL

Rüdiger Hehlmann, MD, PhD, Heidelberg University, Heidelberg, Germany, gives a presentation on advances in treatments for chronic myeloid leukemia (CML), managing CML in the third-line setting, and tyrosine kinase discontinuation (TKI) at the 14th International Congress on Myeloproliferative Neoplasms (MPNs) held in New York City, NY.